No abstract
Patients with pleural effusions frequently present a diagnostic and therapeutic challenge. The diagnosis is based on the interpretation of the results of thoracentesis or pleural biopsy. When a malignant tumor metastasizes to the pleura, tumor cells can be seeded over the mesothelial surface or in the subserous layer. In the former situation, tumor cells are abundant in pleural fluid, but in the latter, few malignant cells are exfoliated into the pleural cavity, and microscopic deposits may not be visualized at thoracoscopy. Pleural lavage cytologic study at the time of thoracoscopy has not been studied. The purpose of this study was to assess the value of thoracoscopic pleural lavage as an adjuvant in the diagnostic workup of patients with exudative pleural effusions. Fifty patients with exudative pleural effusions were investigated by pleural fluid cytologic findings, Abram's pleural biopsy, thoracoscopy, and pleural lavage cytologic findings. After aspiration of all pleural fluid, 300 mL saline was instilled into the pleural cavity and then recovered for cytologic analysis. The final diagnoses were 32 malignant (64%), 15 tuberculous (30%), and 3 idiopathic (6%) effusions. In the malignant group, thoracoscopic biopsy had the highest yield (94%) followed by lavage cytologic analysis (84%), fluid cytologic analysis (62%), and biopsy with Abram's needle (50%). The sensitivity of combined thoracoscopy and lavage cytologic analysis was 96%. In the patients with tuberculous pleuritis, the yield from the pathologic examination of the biopsy specimen was 93% with thoracoscopy and 60% with the Abrams needle. The diagnostic yield with cytologic analysis on pleural lavage fluid is significantly higher than that on pleural fluid. This is probably because the cells in the lavage fluid are fresher and better preserved than those in the regular pleural fluid, which may have undergone degenerative changes, yielding false-negative results. Pleural lavage cytologic analysis should be performed in patients with suspected malignant pleural effusion who are subjected to diagnostic thoracoscopy, because it may provide additional information to thoracoscopic biopsy.
Available online on: 15.01.2018@http://ijrdpl.co m http://dx. ABSTRACT: Background: rational prescription of antibiotics in acute exacerbation of COPD (AECOPD) requires predictive markers. Acute phase reactants are capable of demonstrating the inflammation; however, they cannot be employed to make a difference between bacterial and non-bacterial causes of the inflammation. The bacterial infection plays an important role in the exacerbation of COPD patients. Recently, measurement of serum procalcitonin levels appears to be useful in order to minimize this problem. We aim to evaluate the prognostic and diagnostic. Methods & methods: 51 COPD patients with bacterial exacerbations, 47 patients without bacterial exacerbations, similar age and sex were included in the study. PCT levels in the serum samples were measured in all subjects. Results: Procalcitonin levels ranged from 0.01 to 12.03 ng/ml. Mean levels were 3.18±2.60 ng/ml in Group I and 0.23±0.39 ng/ml in Group II. Median values in Groups I and II were 2.98 and 0.09 ng/ml respectively. Statistically, there was a significant difference between two groups (p<0.001) with Group I showing a higher mean value as compared to Group II. A significant near strong correlation was observed between TLC levels and serum Proclacitonin levels (r=0.699; p<0.001). However, a weak negative and borderline significant correlation. Conclusions: This study found increased PCT serum levels among AECOPD patients and suggests a role for PCT in the predicting of the bacterial exacerbations and their needs for ventilator support. We recommend other large studies to au gment our findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.